Find the right fit for you - faster
Get tailored insights about working at Abeona Therapeutics in one quick step.
Abeona Therapeutics Snapshot
Working together to find cures and advance treatments for patients with rare diseases.
We are dedicated to developing novel treatments for patients with rare diseases through advances in biotechnology, emerging insights in genetics, and in strategic collaboration with researchers, clinicians, stakeholders, regulators, and patient groups.
We are dedicated to developing novel treatments for patients with rare diseases through advances in biotechnology, emerging insights in genetics, and in strategic collaboration with researchers, clinicians, stakeholders, regulators, and patient groups.
Abeona Therapeutics Inc.(NASDAQ: $ABEO)is a leading clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM™, for next generation product candidates.
